Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults (review of TA133 and TA201) and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 21 March 2013.
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): final appraisal determination document
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): consultee and commentator coments on the ACD
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): comments on the ACD received from the public through the NICE website
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Assessment Group's additional analyses
This page was last updated: 21 January 2014